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Introduction: In a double-blind, placebo-controlled trial (EudraCT identifier: 2006-001795-20),
the standardised quality (SQ) house dust mite (HDM) sublingual immunotherapy (SLIT)-tablet
(ALK, Denmark) was investigated.
Method: The trial included 604 subjects, 14 years, with mild-moderate HDM allergic asthma.
Subjects were randomised 1:1:1:1 to 1, 3 or 6 SQ-HDM or placebo once daily. The primary
endpoint was reduction in inhaled corticosteroid (ICS) after one year. ICS reduction, asthma
quality of life questionnaire (AQLQ) and asthma control questionnaire (ACQ) score was ana-
lysed post hoc in a subgroup with daily ICS use of 400e800 mg and ACQ score of 1e1.5, corre-
sponding to partly controlled asthma (N Z 108).
Results: The trial met its primary endpoint. In the subgroup, the difference between placebo
and 6 SQ-HDM in change from baseline in daily ICS use was 327 mg (p < 0.0001), while it was
0.52 (p Z 0.010) for AQLQ. The treatment effect on ICS reduction and AQLQ was increased
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Allergic rhinitis and asthma are increasingly common dis-
eases of the respiratory tract. They often co-exist, with
symptoms of rhinitis found in 75e80% of patients with
asthma [1]. Asthma and bronchial hyper responsiveness are
more common and severe with perennial allergies (e.g.
house dust mite (HDM) and cat dander allergy) compared to
seasonal allergies [2,3].
Asthma is associated with substantial indirect costs that
increase significantly as disease control decreases [4].
Although the costs of rhinitis and asthma are independently
high, medical care costs are higher in those with asthma
and rhinitis compared with those with asthma alone [5].
Allergy immunotherapy (AIT) addresses the underlying
cause of allergy through immunomodulation, and thus
treats both manifestations of respiratory allergic disease.
Subcutaneous immunotherapy (SCIT) has been shown to
reduce the use of inhaled corticosteroid (ICS) in adults and
children with house dust mite (HDM) related asthma [6,7].
Further, a trial with 3 years of standardized SCIT treat-
ment, suggested a preventive effect on development of
asthma in children with seasonal rhinitis [8e10]. Recently,
evidence was published on reduction of seasonal asthma
symptoms in grass pollen allergic children and adults by
treatment with a standardised quality (SQ) grass tablet for
sublingually administered AIT (SLIT) [11,12]. However,
investigation of AIT in the treatment of asthma was not
included in EMA guidelines until recently [13e15], and its
benefits are being debated in global treatment guidelines
[16].
A trial investigating the effect of SQ HDM SLIT-tablet in
HDM respiratory allergic disease, based on reduction in
daily use of ICS (standardised to budesonide), has been
conducted [17]. The trial showed a statistically significant
treatment effect on ICS use in favour of the highest dose
group (6 SQ-HDM1) without affecting asthma control end-
points; implying a reduced ICS dose required to maintain
asthma control. As a substantial number of asthma patients
worldwide is suffering from severe asthma [18] and thus is
being at higher risk of frequent exacerbations [19], the
medical need for new treatments in asthma is more perti-
nent for the severe part of the trial population.
Therefore, the present post hoc subgroup analysis
included subjects with a mediumehigh dose use of ICS2 drug substances: allergen
atophagoides pteronyssinus
e standardised against an in-
ctivity.(>400 mg ICS per day) but still only partly controlled by the
ICS and thus having a medical need for additional
treatment.Methods
Full information about the trial is published elsewhere [17].
Briefly, the trial was a multi-national, multiple-dose,
randomised, double-blind, parallel-group, placebo-
controlled trial including 604 subjects (EudraCT identifier:
2006-001795-20). Written informed consent was obtained
from all subjects (and parents/guardians for subjects below
18 years) before any trial related procedures, in accor-
dance with the Declaration of Helsinki. Main inclusion
criteria included: 14 years or above; a clinical history of
HDM-related mild to moderate persistent asthma (defined
as medication steps 2 and 3 in GINA 2002 [20]); daily use of
ICS (corresponding to 100e800 mg budesonide/day) for
control of asthma symptoms, a clinical history consistent
with HDM-induced allergic rhinitis, and positive diagnostic
tests (specific IgE and skin prick tests).
The investigational medicinal product (IMP) was a fast-
dissolving oral lyophilisate for sublingual administration.
The active ingredients were standardised extracts of Der-
matophagoides (D.) pteronyssinus and D. farinae in a 1:1
ratio. Placebo was similar in appearance, smell and taste,
but without active ingredients. Subjects were randomised
(1:1:1:1) to double-blind, daily treatment with 1, 3 or 6 SQ-
HDM SLIT-tablet (ALK, Denmark) or placebo for approxi-
mately 12 months.
The trial design is shown in Fig. 1. Prior to random-
isation, ICS use was standardised to budesonide and
tapered to the lowest possible ICS dose to maintain
adequate asthma control as defined by an asthma control
questionnaire (ACQ) score <1.5 [21,22]. The lowest ICS
dose was found by reducing the subject’s ICS dose in steps
with intervals of 3e4 weeks until loss of control (as defined
by an ACQ score of >1.5) was provoked. Hereafter, the ICS
dose was increased to the previous step to regain control
(ACQ score <1.5). The tapering was followed by an ICS
stable period, regarded as a baseline period prior to ran-
domisation. The primary endpoint was reduction in ICS use
after one year of treatment, assessed by a new ICS tapering
and ICS stable period.
The subgroup described here, includes the subset of the
trial population with a mediumehigh dose use of ICS and
partly controlled asthma. In practise, subjects in the sub-
group were selected by ICS use of 400e800 mg/day and an
ACQ score of 1e1.5 at randomisation. Within this range,
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Figure 1 Overall trial design.
1432 F. de Blay et al.ICS reduction from baseline, asthma control by means of
the ACQ questionnaire, and asthma quality of life by means
of the asthma quality of life questionnaire with stand-
ardised activities (AQLQ(S) [23,24]) were investigated.
Adverse events (AEs) were reported in agreement with
ICH guidelines (described in details elsewhere [17]). AEs
occurring after first IMP intake and reported by subjects in
the subgroup are included here.Table 1 Baseline ICS use, AQLQ(S) and ACQ score in sub-







Subgroup FAS Subgroup FAS Subgroup FAS
Overall 615 449 5.61 5.97 1.18 0.80
Placebo 641 465 5.52 5.94 1.20 0.82
1SQ-HDM 636 438 5.75 6.08 1.21 0.80
3SQ-HDM 648 433 5.58 5.93 1.16 0.81
6SQ-HDM 541 462 5.62 5.92 1.15 0.77
ICS: inhaled corticosteroid (here: budesonide); AQLQ(S):
(standardised version of) asthma quality of life questionnaire;
ACQ: asthma control questionnaire; Subgroup: subjects with
daily ICS use of 400e800 mg and ACQ score of 1e1.5 (NZ 108);
FAS: full analysis set (N Z 604).Statistics
For ICS reduction, treatment groups were compared with a
linear mixed model using data from all 4 treatment groups.
The model included treatment group and baseline ICS dose
(recorded for the ICS stable periods) as fixed effects and
trial site as a random effect. Two-sided 95% confidence
intervals for the adjusted mean differences are presented
as well as the corresponding p-values. The categorical
variable of relative reduction in ICS use was summarised by
frequency.
The ACQ includes 7 questions (5 symptoms, forced
expiratory volume in the first second (FEV1) in % of pre-
dicted value, and short-acting bronchodilator use). Sub-
jects were to recall how their asthma had been during the
previous week and to respond to the symptom and bron-
chodilator use questions on a 7-point scale from 0 (no
impairment) to 6 (maximum impairment). Clinic staff
scored FEV1% predicted according to a specified 7-point
scale. The questions were equally weighted and the ACQ
score was the mean of the 7 questions and therefore be-
tween 0 and 6. The analysis of change from baseline for the
average overall ACQ score (averaged over the ICS stable
periods) was performed with a linear mixed model similarly
to the ICS reduction analysis.
The AQLQ(S) comprises 32 questions in four domains
(symptoms, activity limitation, emotional function and
environmental stimuli), each scored on a 7-point scale from
1 (maximum impairment) to 7 (no impairment). When
responding, subjects were to recall their experience during
the last 2 weeks. Overall scores and domain scores werecalculated for each subject at baseline (end of baseline ICS
stable period) and at the end-of-trial visit. The change from
baseline to end-of-trial was calculated for each subject and
analysed similarly to the ICS reduction with a linear mixed
model including treatment group and baseline value as
fixed effects and site as random effect.
The impact of belonging to the subgroup was analysed in
a linear mixed model including site as random effect and
treatment group, baseline value (ICS/AQLQ(S)), subgroup
(Y/N) and interaction of subgroup with treatment (Y/N) as
fixed effects.
The analyses of ICS reduction, ACQ, and AQLQ in the
subgroup correspond to the pre-defined analyses for the full
analysis set. The subgroup analyses are considered explor-
atory and no multiplicity control has been applied.Results
Subgroup demographics
The subgroup included 108 subjects (18% of the full analysis
set) equally distributed over the 4 treatment groups. 98
SQ HDM SLIT-tablet in treatment of asthma 1433subjects (91%) completed the trial, while 10 subgroup
subjects discontinued the trial prematurely due to with-
drawal of consent (N Z 1), lost to follow up (N Z 4), non-
compliance with protocol (NZ 3), or AEs (NZ 2; both from
the 3 SQ-HDM group). Baseline demographics for the sub-
group resembled the full analysis set, though the subgroup
were slightly older (mean age 34.7 years versus 31.1 years)
and had asthma and rhinitis for a correspondingly longer
period of time.
The mean ICS use at randomisation for the subgroup was
615 mg, compared with 449 mg in the full analysis set (Table
1). The mean AQLQ(S) score was 5.61 in the subgroup versus
5.97 in the full analysis set and the mean ACQ score was
1.18 in the subgroup versus 0.80 in the full analysis set
(Table 1).Figure 2 A) Change from baseline in adjusted mean daily ICS
use (mg); B) Average ACQ score; and C) Average overall AQLQ(S)
score; all at end-of-trial with difference to placebo in
numbers; *: p < 0.05; **: p < 0.001.Efficacy
The trial met its primary endpoint, with a statistically sig-
nificant difference in the ICS reduction between 6 SQ-HDM
and placebo (81 mg/day, [CI95%: 27e136 mg/day],
p Z 0.004). In the subgroup, the difference in adjusted
mean to placebo in the 6 SQ-HDM group during the end of
trial ICS stable period was 327 mg/day, [CI95%: 182e471 mg/
day], p < 0.0001 (see Fig. 2A). The ICS reduction in the 1
SQ-HDM and 3 SQ-HDM groups was less pronounced and not
significantly different from placebo. The effect of the
interaction of subgroup with treatment was statistically
significant (p < 0.001), implying that the treatment effect
on ICS reduction was increased for the subgroup as
compared to the residual group.
In the 6 SQ-HDM group, 17 subjects (59%) were able to
reduce ICS use by 75%e100% without impairment in asthma
control (Table 2), and 13 subjects (45%) withdrew ICS use
completely. In the placebo group 1 subject (4%) was able to
withdraw ICS. No subjects on 6 SQ-HDM increased their ICS
use during the 1-year trial, while this was the case for 5
subjects (19%) in the placebo group (Table 2).
Lung function (in terms of mean FEV1) was around 85% of
predicted value in all treatment groups at all visits during
the trial (mean changes from randomisation were within
4% with no apparent pattern; data not shown).
The difference from baseline in overall ACQ score at the
end of trial ICS stable period was statistically significantly
lower in the 6 SQ-HDM group than in the placebo group
(difference: 0.41, p Z 0.0002; see Fig. 2B), implying
better asthma control after treatment in the 6 SQ-HDM
group. In the 1 SQ-HDM and 3 SQ-HDM groups, differences
were not statistically significant.
There was also a statistically significant difference in
asthma quality of life between placebo and 6 SQ-HDM in
terms of a difference in overall AQLQ(S) scores of 0.52,
p Z 0.010 (see Fig. 2C). The differences to placebo were
lower in the 1 SQ-HDM and 3 SQ-HDM groups (0.30 and 0.32)
and not statistically significant. The difference to placebo
in the subgroup was significantly higher than for the rest of
the population (p Z 0.044).
The increased AQLQ(S) score in the 6 SQ-HDM group was
primarily related to the symptoms domain (difference to
placebo 0.61, p Z 0.006) and to the activity limitation
domain (difference to placebo 0.52, p Z 0.011).
Table 2 Relative reduction in ICS use for the subgroup from randomisation to end of trial.
Reduction in ICS Placebo (N Z 27) 1 SQ-HDM (N Z 25) 3 SQ-HDM (N Z 27) 6 SQ-HDM (N Z 29)
N % N % N % N %
75%e100% 1 (4%) 6 (24%) 5 (19%) 17 (59%)
50%e<75% 4 (15%) 5 (20%) 5 (19%) 3 (10%)
25%e<50% 6 (22%) 4 (16%) 2 (7%) 2 (7%)
0%e<25% 11 (41%) 7 (28%) 9 (33%) 7 (24%)
<0% 5 (19%) 3 (12%) 6 (22%) 0 (0%)
ICS: inhaled corticosteroid (here: budesonide); Subgroup: subjects with daily ICS use of 400e800 mg and asthma control questionnaire
score of 1e1.5 (N Z 108).
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Treatment was well-tolerated by all subjects in the sub-
group. The numbers, causality and severity of reported AEs
in the subgroup are in line with what was reported for the
full analysis set [17]. There was a dose-dependent increase
in IMP-related AEs (defined as possibly or probably related
to the IMP), from 0.1 IMP-related AEs/subject in the pla-
cebo group to 1.1 IMP-related AEs/subject in the 6 SQ-HDM
group (see Fig. 3), but the majority of AEs were mild or
moderate in intensity and only 5 severe AEs (bacterial
infection in the 1 SQ-HDM group, phlebitis, alopecia areta,
nasopharyngitis and foot fracture in the 3 SQ-HDM group)
were reported.
The most frequent AEs were oral pruritus, nasophar-
yngitis, asthma, and ear pruritus, with nasopharyngitis
being reported with similar frequency in active and placebo
groups while oral pruritus, asthma, and ear pruritus were
more frequent in the active groups than in placebo. There
was a higher incidence of reporting of asthma as an AE in
the subgroup (11 subjects, 10%) as compared with the full
analysis set (18 subjects, 3%).
No IMP-related serious (as per ICH E2A definitions [25])
AEs were reported.Discussion
This post hoc analysis on a subgroup from a phase II/III DBPC
trial on SQ HDM SLIT-tablet [17] showed that subjects with a
daily ICS use of 400e800 mg and partly controlled asthma
(defined as ACQ score between 1 and 1.5) at randomisation
had significantly higher treatment effect in terms of ICS
reduction than the residual trial population with less severe
asthma. Additionally, the 6 SQ-HDM group had significant
improvements in asthma control and asthma-related qual-
ity of life at the end of trial (i.e. after one year of AIT
treatment). The HDM-tablet was well-tolerated and effec-
tive in this subgroup, with a safety profile similar to the full
analysis set. The trial provides proof of concept for SQ HDM
SLIT-tablet in the treatment of asthma, and the subgroup
analysis suggests that the most favourable benefiterisk
profile may be expected in patients with partly controlled
HDM allergic asthma despite mediumehigh dose use of ICS.
Per definition, results from post hoc analyses should be
interpreted with caution, and the hypothesis created
should be confirmed in new trials before firm conclusions
can be drawn. The low p-value (<0.0001) for ICS reductionin this subgroup, reduces the likelihood of the result being a
type I error (a false positive). A phase III trial has recently
been conducted, confirming the efficacy of HDM AIT-tablet
in asthma in a population resembling this subgroup
(manuscript in preparation). To fulfil regulatory re-
quirements, the primary endpoint in this trial was modified
to measure asthma control shown by risk reduction for
asthma exacerbations during ICS reduction, rather than
through maintained control during ICS reduction (EudraCT
#2010-018621-19). This is in line with the GINA update from
2011, where focus is increasingly placed on asthma control
[16].
Asthma control can both be defined in the short term by
achieving good control of the current clinical manifesta-
tions of asthma, and in the long term by reducing risk to the
patient (i.e. the risk of adverse outcomes such as exacer-
bations, poor control, accelerated decline in lung function,
and side effects of treatment) [26]. Some of these risks may
result from lack of control of the underlying disease pro-
cess. AIT is the only treatment of respiratory allergy that
treats the underlying cause of the disease and therefore
has disease-modifying potential. This potential has been
confirmed in trials with the corresponding grass SLIT-tablet
[12,27]. As immunotherapy targets the immunological
background in allergic asthma, it is expected to lead to
long-term improvement of asthma [28], but this remains to
be documented. The potential of the grass SLIT-tablet to
prevent disease progression from allergic rhinitis to allergic
asthma is currently being investigated in the Grazax Asthma
Prevention (GAP) trial [29].
ICS treatment is the cornerstone of asthma therapy in
both children and adults because it targets the airway
inflammation. However, ICS treatment does not alter the
disease progression, and some patients fail to achieve
adequate control. In the described subgroup with partly
controlled asthma, the addition of 6 SQ-HDM for one year
not only increased asthma control significantly, but resul-
ted in a significant reduction of ICS and a clinically relevant
improvement in asthma-related quality of life. The design
of the trial with ICS tapering periods is by nature an arti-
ficial set-up, yet in agreement with the GINA strategy for
asthma management, stating the importance of establish-
ing the lowest dose of treatment necessary to maintain
control [16]. The level of reduction in ICS was comparable
to that of montelukast [30] and theophylline [31].
A dilemma for use of AIT in the treatment of asthma is
that patients with severe asthma are at increased risk in
case of systemic adverse events as these may trigger severe
Figure 3 The bars show numbers of AEs reported in the subgroup per treatment group and according to investigator assessed
causality (left y-axis). The line shows numbers of related (probable or possible) AEs per subject (right y-axis).
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ence from subcutaneous products and has led to some AIT
products being contraindicated for patients with severe or
uncontrolled asthma. Based on the GINA 2002 definitions of
asthma severity [20], patients with FEV1 below 70% of
predicted value with appropriate medication were
excluded from the present trial. In the subgroup, all sub-
jects had FEV1 around 85% of predicted value at random-
isation, which is within limits of normal FEV1. With the
updated GINA terminology [32], which puts focus on control
rather than severity, a post hoc analysis of control status
for the full trial population based on ACQ items was
included in the primary publication of this trial [17]. The
analysis showed that part of the population was in fact
uncontrolled by means of frequent symptoms or nocturnal
awakenings, and data confirmed that lung function in terms
of FEV1 contributed little to the asthma control
classification.
Together with the benign safety profile shown for HDM
SLIT-tablet in the subgroup and the significantly increased
disease-specific quality of life in the 6 SQ-HDM group, our
data suggest that in patients with partly or even uncon-
trolled asthma according to GINA definitions, whose lung
function is not severely impaired, treatment with SQ HDM
SLIT-tablet may be well tolerated and beneficial in terms of
increased asthma control.
Conclusion
In a subgroup with partly controlled HDM-related asthma
despite mediumehigh daily dose of ICS, the benefit of
treatment with SQ HDM SLIT-tablet for 1 year was signifi-
cantly higher than for the entire trial population with less
severe asthma. Despite statistically significantly lowered
ICS dose in the 6 SQ-HDM group, the subjects reported
improved asthma-related quality of life as well as asthma
control. Treatment was well-tolerated in the subgroup
population.
Thus, this post-hoc analysis suggest, that patients with
HDM related asthma, who are not adequately controlled on
mediumehigh daily doses of ICS, may benefit significantlyfrom SQ HDM SLIT-tablet treatment, both in terms of
increased asthma control (as shown by reduced need for ICS
and reduced ACQ score) and improved quality of life.Conflicts of interest
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